Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexicon Pharmaceuticals (LXRX) Depreciation & Amortization (CF) (2023 - 2025)

Lexicon Pharmaceuticals (LXRX) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $118000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 5.6% to $118000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $621000.0, a 16.29% increase, with the full-year FY2025 number at $621000.0, up 16.29% from a year prior.
  • Depreciation & Amortization (CF) was $118000.0 for Q4 2025 at Lexicon Pharmaceuticals, down from $151000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $176000.0 in Q1 2025 to a low of $112000.0 in Q1 2023.
  • A 3-year average of $142416.7 and a median of $144000.0 in 2023 define the central range for Depreciation & Amortization (CF).
  • Biggest YoY gain for Depreciation & Amortization (CF) was 28.57% in 2024; the steepest drop was 16.56% in 2024.
  • Lexicon Pharmaceuticals' Depreciation & Amortization (CF) stood at $147000.0 in 2023, then dropped by 14.97% to $125000.0 in 2024, then decreased by 5.6% to $118000.0 in 2025.
  • Per Business Quant, the three most recent readings for LXRX's Depreciation & Amortization (CF) are $118000.0 (Q4 2025), $151000.0 (Q3 2025), and $176000.0 (Q2 2025).